January-March 2018

Apo B/Apo A1 Ratio: A Risk Marker in Patients with Cardiovascular Disease

Chitra A. Sathe1*, Shubha A. Chogle2, Disha Bharadwaj3

1Associate professor, 3M.Sc, Department of Biochemistry, Seth G.S Medical College and K.E.M Hospital, Parel, Mumbai- 400012

2Biochemist, Department of Pathology, Breach Candy Hospital Trust, 60 A, Bhulabhai Desai Road, Mumbai – 400026


BACKGROUND AND OBJECTIVES: Cardiovascular disease (CVD) is a broad term encompassing diseases of the heart and blood vessels.The lipid and lipoprotein cholesterol levels have failed to explain the increased prevalence of CVD in normolipidemic patients. Recently ApoA1 and Apo B have been proposed as markers for assessing the risk of CVD and its treatment regimen. The purpose of this study was to determine whether the Apo B/Apo A1 ratio was superior to the conventional lipid parameters in predicting the risk of a CVD. METHOD: A total of 45 subjects were included in the study. The plasma levels of Apo A1, Apo B and the lipid parameters were determined on VITROS 4600 Chemistry System. The Apo B/Apo A1, LDL-C/HDL-C and total cholesterol/HDL-C ratio were then calculated. RESULTS: After analysing the data obtained and comparing the data with control group in whom the Apo B/Apo A1 ratio was below 0.6 patients with Apo B/Apo A1 ratio exceeding 0.9 were included in the high risk group and patients with Apo B/Apo A1 ratio between 0.6-0.9 were included in the average risk group.CONCLUSION: According to the results obtained it was concluded that subjects with Apo B/Apo A1 ratio exceeding 0.9 were at an increased cardiovascular risk as compared to subjects with Apo B/Apo A1 ratio less than 0.6 who were at a lower risk of developing a cardiovascular event. The Apo B/Apo A1 ratio was thus found to have better predictive value than that of classical lipid parameters in cardiovascular assessment.

Keywords: Cardiovascular, lipoprotein, Apo B, Apo A1

[Full Text Article]  
Twitter Links